Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSENT: AM-111 for Acute Sudden Sensorineural Hearing Loss
2016-005166-58Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jul 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brimapitide in idiopathic sudden sensorineural hearing loss (ISSNHL), sponsored by Altamira Therapeutics. Started Jul 2017; status: completed.
02
Drugs
brimapitide
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on 2016-005166-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005166-58.